Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575367 · ClinicalTrials.gov registry record · Phase 4
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
A Phase 4 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT00575367: Completed Phase 4 study, sponsored by Merck Sharp & Dohme.
NCT00575367 is a Phase 4 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 37 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00575367, a Phase 4 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers
Interventions
- DRUG AzaSite (azithromycin ophthalmic solution)
- DRUG Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-03 |
| Phase | Phase 4 |
What the finished NCT00575367 record still lists
NCT00575367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which AzaSite (azithromycin ophthalmic solution) is the first listed.
NCT00575367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00575367 about?
NCT00575367 is a clinical study titled "Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers". The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers
What is the current status of trial NCT00575367?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00575367?
The interventions under investigation include: AzaSite (azithromycin ophthalmic solution) (DRUG), Vigamox (moxifloxacin hydrochloride ophthalmic solution) (DRUG).
Who is sponsoring clinical trial NCT00575367?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00575367's enrollment target sits among peer trials
37 1482nd of 2000 higher than 511 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia